AXGT - Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present at upcoming conferences and will announce six-month safety and efficacy data from the second cohort of its AXO-Lenti-PD program the morning of Tuesday, October 6, 2020. Additionally, as previously announced the Company will hold a Parkinson’s Disease R&D Day on Friday, October 30.
Information on the upcoming presentations can be found below:
Chardan 4 th Annual Genetic Medicines Conference
| Date: |
| Tuesday, October 6, 2020 |
| Time: |
| 2:30 PM ET |
| Participation Format: |
| Fireside chat with Gbola Amusa, MD, CFA (Head of HC Research) |
| Webcast link: |
| https://wsw.com/webcast/chard6/axgt/1861600 |
| Axovant will participate in 1x1 investor meetings during the conference |
2020 ARM Virtual Cell and Gene Meeting on the Mesa
| Date: |
| Tuesday, October 13, 2020 |
| Time: |
| 12:00 PM PT/3:00 PM ET |
| Presentation Format: |
| Panel discussion: Cell and Gene Therapies for Chronic Conditions |
| Presenter: |
| Pavan Cheruvu, MD, Chief Executive Officer, Axovant Gene Therapies |
AXO-Lenti-PD Parkinson’s Disease R&D Day
| Date: |
| Friday, October 30, 2020 |
| Time: |
| 11:30 AM – 1 PM ET |
| Moderator: |
| Gavin Corcoran, MD, Chief R&D Officer, Axovant Gene Therapies |
| Registration link: |
| https://lifescipartners.zoom.us/webinar/register/8316004583906/WN_F19FymdTQIGjki6Bb-veIw |
A live webcast of the presentations will be available in the Events section of Axovant's website at www.axovant.com . Replays will be available for approximately 30 days following the conferences.
About Axovant Gene Therapies
Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com .
Contacts:
Media & Investors
Parag Meswani
Axovant Gene Therapies Ltd.
(212) 547-2523
media@axovant.com
investors@axovant.com